Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
In February 2006, a live, oral, human-bovine reassortant rotavirus vaccine (RotaTeq) was licensed for use among U.S. infants. The Advisory Committee on Immunization Practices recommends routine vaccination of U.S. infants with 3 doses of this rotavirus vaccine administered orally at ages 2, 4, and 6 months. The first dose should be administered between ages 6-12 weeks. Subsequent doses should be administered at 4-10 week intervals, and all 3 doses should be administered by age 32 weeks. Rotavirus vaccine can be co-administered with other childhood vaccines. Rotavirus vaccine is contraindicated for infants with a serious allergic reaction to any vaccine component or to a previous dose of vaccine.
Parashar
Umesh D
UD
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Rd., NE. MS A-34, Atlanta, GA 30333, USA. uap2@cdc.gov
Alexander
James P
JP
Glass
Roger I
RI
D002675:Child, Preschool; D000075202:Contraindications; D005759:Gastroenteritis / Q000517:prevention & control* / Q000821:virology*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D012400:Rotavirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects
C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated